234 related articles for article (PubMed ID: 25353097)
1. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients.
Jiang H; Gebhardt C; Umansky L; Beckhove P; Schulze TJ; Utikal J; Umansky V
Int J Cancer; 2015 May; 136(10):2352-60. PubMed ID: 25353097
[TBL] [Abstract][Full Text] [Related]
2. Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab.
Gebhardt C; Sevko A; Jiang H; Lichtenberger R; Reith M; Tarnanidis K; Holland-Letz T; Umansky L; Beckhove P; Sucker A; Schadendorf D; Utikal J; Umansky V
Clin Cancer Res; 2015 Dec; 21(24):5453-9. PubMed ID: 26289067
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients.
Jordan KR; Amaria RN; Ramirez O; Callihan EB; Gao D; Borakove M; Manthey E; Borges VF; McCarter MD
Cancer Immunol Immunother; 2013 Nov; 62(11):1711-22. PubMed ID: 24072401
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma.
Chevolet I; Speeckaert R; Schreuer M; Neyns B; Krysko O; Bachert C; Van Gele M; van Geel N; Brochez L
J Transl Med; 2015 Jan; 13():9. PubMed ID: 25592374
[TBL] [Abstract][Full Text] [Related]
5. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth.
Schlecker E; Stojanovic A; Eisen C; Quack C; Falk CS; Umansky V; Cerwenka A
J Immunol; 2012 Dec; 189(12):5602-11. PubMed ID: 23152559
[TBL] [Abstract][Full Text] [Related]
6. Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?
Chevolet I; Schreuer M; Speeckaert R; Neyns B; Hoorens I; van Geel N; Krüse V; Hennart B; Allorge D; Van Gele M; Brochez L
Melanoma Res; 2015 Aug; 25(4):357-61. PubMed ID: 26050145
[TBL] [Abstract][Full Text] [Related]
7. Cyclophosphamide promotes chronic inflammation-dependent immunosuppression and prevents antitumor response in melanoma.
Sevko A; Sade-Feldman M; Kanterman J; Michels T; Falk CS; Umansky L; Ramacher M; Kato M; Schadendorf D; Baniyash M; Umansky V
J Invest Dermatol; 2013 Jun; 133(6):1610-9. PubMed ID: 23223128
[TBL] [Abstract][Full Text] [Related]
8. Local immunosuppressive microenvironment enhances migration of melanoma cells to lungs in DJ-1 knockout mice.
Chien CH; Lee MJ; Liou HC; Liou HH; Fu WM
PLoS One; 2015; 10(2):e0115827. PubMed ID: 25706411
[TBL] [Abstract][Full Text] [Related]
9. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
[TBL] [Abstract][Full Text] [Related]
10. Interferon alpha-induced reduction in the values of myeloid-derived suppressor cells in melanoma patients.
Stanojević I; Gavević M; Jović M; Mijugković Z; Zevević R; Zolotarevski L; Jauković L; Rajović M; Novaković M; Binić I; Vojvodić D
Vojnosanit Pregl; 2015 Apr; 72(4):342-9. PubMed ID: 26040180
[TBL] [Abstract][Full Text] [Related]
11. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer.
OuYang LY; Wu XJ; Ye SB; Zhang RX; Li ZL; Liao W; Pan ZZ; Zheng LM; Zhang XS; Wang Z; Li Q; Ma G; Li J
J Transl Med; 2015 Feb; 13():47. PubMed ID: 25638150
[TBL] [Abstract][Full Text] [Related]
12. Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab.
Sade-Feldman M; Kanterman J; Klieger Y; Ish-Shalom E; Olga M; Saragovi A; Shtainberg H; Lotem M; Baniyash M
Clin Cancer Res; 2016 Dec; 22(23):5661-5672. PubMed ID: 27178742
[TBL] [Abstract][Full Text] [Related]
13. Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas.
Fujimura T; Ring S; Umansky V; Mahnke K; Enk AH
J Invest Dermatol; 2012 Apr; 132(4):1239-46. PubMed ID: 22189788
[TBL] [Abstract][Full Text] [Related]
14. Presence of circulating Her2-reactive CD8 + T-cells is associated with lower frequencies of myeloid-derived suppressor cells and regulatory T cells, and better survival in older breast cancer patients.
Bailur JK; Gueckel B; Derhovanessian E; Pawelec G
Breast Cancer Res; 2015 Mar; 17(1):34. PubMed ID: 25849846
[TBL] [Abstract][Full Text] [Related]
15. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.
Weide B; Martens A; Zelba H; Stutz C; Derhovanessian E; Di Giacomo AM; Maio M; Sucker A; Schilling B; Schadendorf D; Büttner P; Garbe C; Pawelec G
Clin Cancer Res; 2014 Mar; 20(6):1601-9. PubMed ID: 24323899
[TBL] [Abstract][Full Text] [Related]
16. Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients.
Rudolph BM; Loquai C; Gerwe A; Bacher N; Steinbrink K; Grabbe S; Tuettenberg A
Exp Dermatol; 2014 Mar; 23(3):202-4. PubMed ID: 24495013
[TBL] [Abstract][Full Text] [Related]
17. Melanoma-induced immunosuppression and its neutralization.
Umansky V; Sevko A
Semin Cancer Biol; 2012 Aug; 22(4):319-26. PubMed ID: 22349515
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.
de Coaña YP; Wolodarski M; Poschke I; Yoshimoto Y; Yang Y; Nyström M; Edbäck U; Brage SE; Lundqvist A; Masucci GV; Hansson J; Kiessling R
Oncotarget; 2017 Mar; 8(13):21539-21553. PubMed ID: 28423487
[TBL] [Abstract][Full Text] [Related]
19. Serum inflammatory factors and circulating immunosuppressive cells are predictive markers for efficacy of radiofrequency ablation in non-small-cell lung cancer.
Schneider T; Sevko A; Heussel CP; Umansky L; Beckhove P; Dienemann H; Safi S; Utikal J; Hoffmann H; Umansky V
Clin Exp Immunol; 2015 Jun; 180(3):467-74. PubMed ID: 25644608
[TBL] [Abstract][Full Text] [Related]
20. Circulating and Tumor Myeloid-derived Suppressor Cells in Resectable Non-Small Cell Lung Cancer.
Yamauchi Y; Safi S; Blattner C; Rathinasamy A; Umansky L; Juenger S; Warth A; Eichhorn M; Muley T; Herth FJF; Dienemann H; Platten M; Beckhove P; Utikal J; Hoffmann H; Umansky V
Am J Respir Crit Care Med; 2018 Sep; 198(6):777-787. PubMed ID: 29617574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]